Actinogen Medical on Track for November XanaMIA Alzheimer's Trial Results
Actinogen Medical (ACW.AX) is preparing to release top-line results from its pivotal Phase 2b/3 XanaMIA trial in November 2026, as highlighted by CEO Dr. Stephen Gourlay during a recent interview with Proactive. The fully enrolled Alzheimer's disease study remains on schedule and has passed the third safety review by an independent Data Monitoring Committee without requiring amendments. With $16.7 million in cash at the end of its June quarter, CFO Will Souter stated that current funding should support operations through to mid-2027. Gourlay also noted positive depression trial data published in a reputable journal and ongoing regulatory discussions with bodies like the FDA and EMA. The company is exploring additional financial resources such as an R&D tax rebate and potential option exercises, which could further extend its runway beyond key milestones.
Topics: Alzheimer's disease funding status trial progress XanaMIA drug candidate